Towards (99m)Tc-based imaging agents with effective doxorubicin mimetics: a molecular and cellular study
S Imstepf1, V Pierroz2, P Raposinho3
1Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
Dalton Transactions (Cambridge, England : 2003)
|April 21, 2016
Summary
Researchers developed Doxorubicin-metalloconjugates for cancer imaging and therapy. These new compounds target cancer cell DNA, showing potent anti-cancer activity and potential as diagnostic imaging agents.
Area of Science:
- Oncology
- Radiochemistry
- Molecular Biology
Background:
- Doxorubicin is a widely used chemotherapy drug targeting DNA in hypermitotic cancer cells.
- Its nuclear accumulation and DNA intercalation suggest potential for novel imaging agents.
Purpose of the Study:
- To design, synthesize, and evaluate Doxorubicin-metalloconjugates for cancer applications.
- To assess their DNA binding, cytotoxicity, and potential as imaging agents.
Main Methods:
- Synthesis of Doxorubicin-metalloconjugates with technetium-99m (99mTc) and rhenium (Re).
- In vitro evaluation of nuclear accumulation, DNA binding, cytotoxicity, and Topoisomerase II inhibition.
Main Results:
- Conjugates showed preferential nuclear accumulation and tight DNA binding.
- Doxorubicin-metalloconjugates retained significant cytotoxicity.
- Rhenium conjugates inhibited human Topoisomerase II, mimicking Doxorubicin's action.
Conclusions:
- Doxorubicin-metalloconjugates effectively mimic Doxorubicin's in vitro profile.
- 99mTc conjugates are promising candidates for nuclear imaging agents.
- Re conjugates show therapeutic potential through Topoisomerase II inhibition.
